Orchestra BioMed (NASDAQ:OBIO) Insider David Hochman Acquires 5,000 Shares

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider David Hochman acquired 5,000 shares of Orchestra BioMed stock in a transaction dated Monday, June 1st. The shares were purchased at an average cost of $3.83 per share, with a total value of $19,150.00. Following the completion of the transaction, the insider directly owned 1,064,029 shares of the company’s stock, valued at $4,075,231.07. This trade represents a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Orchestra BioMed Stock Up 1.0%

Shares of OBIO stock traded up $0.04 on Tuesday, hitting $3.87. 292,725 shares of the stock were exchanged, compared to its average volume of 252,075. The company has a current ratio of 7.03, a quick ratio of 7.01 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $231.62 million, a P/E ratio of -3.89 and a beta of 0.51. The business has a 50-day moving average of $4.18 and a 200 day moving average of $4.28. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.92 million. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%. Equities analysts anticipate that Orchestra BioMed Holdings, Inc. will post -1.47 EPS for the current year.

Hedge Funds Weigh In On Orchestra BioMed

Hedge funds have recently added to or reduced their stakes in the stock. China Universal Asset Management Co. Ltd. bought a new position in Orchestra BioMed during the 4th quarter worth $38,000. Creative Planning bought a new position in Orchestra BioMed during the 2nd quarter worth $40,000. XTX Topco Ltd bought a new position in Orchestra BioMed during the 2nd quarter worth $45,000. Jane Street Group LLC bought a new position in Orchestra BioMed during the 2nd quarter worth $50,000. Finally, Virtu Financial LLC bought a new position in Orchestra BioMed during the 4th quarter worth $57,000. Institutional investors own 53.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Wall Street Zen cut Orchestra BioMed from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. B. Riley Financial lowered their target price on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Orchestra BioMed in a research note on Thursday, May 14th. Chardan Capital reiterated a “buy” rating and set a $20.00 target price on shares of Orchestra BioMed in a research note on Thursday, March 12th. Finally, Barclays increased their target price on Orchestra BioMed from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.